🔎 Trials Near Me

Utama › Aterosklerosis › Louisiana

Kajian klinikal Aterosklerosis di Louisiana

6 kajian untuk Aterosklerosis sedang mencari peserta di lokasi di Louisiana.

Teks kajian rasmi (Bahasa Inggeris)

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

  • Tulane University School of Medicine, New Orleans
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07157774

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Cardiovascular Associates Research, LLC, Covington
  • Tandem Clinical Research - Marrero, Marrero
Mengambil pesertaFasa 3
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Renal Associates of Baton Rouge, Baton Rouge
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

  • Research Site, Covington
  • Research Site, Hammond
  • Research Site, Lake Charles
  • dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT07000357

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

  • Omega Clinical Research, Metairie
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06813911

Pelacarsen Roll-over Extension Program

  • Cardiovascular Associates Research, Covington
  • Omega Clinical Research, Metairie
  • CV Ins of the South, Opelousas
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06875973

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.